A number of genetic mutations have presented immune microenvironment modulatory properties in solid tumors: EGFR mutations correlate with an immunosuppressive TME and may impact the antitumor immune response in NSCLC22,23; TP53 and KRAS mutations in lung adenocarcinoma can regulate the immune microenvironment to affect PD-1 blockade immunotherapy24,25; JAK1 or JAK2 mutations may lead to acquired resistance to PD-1 blockade immunotherapy in patients with melanoma26. This evidence concerns the gene TP53 and lung adenocarcinoma.